Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
Grant Opportunity Analysis
The National Institutes of Health (NIH) is offering a funding opportunity for preclinical proof of concept studies focused on rare diseases through the R21 Exploratory/Developmental Research Grant mechanism. This initiative aims to support efficacy studies in established rare disease models to validate therapeutic agents, including small molecules and biologics, that address significant unmet medical needs. With approximately 30 million Americans affected by rare diseases, this funding opportunity seeks to bridge the gaps in drug development and propel promising agents towards clinical trials. Interested applicants can apply for a maximum budget of $275,000 over a two-year project period, with applications opening on May 3, 2024, and a close date of June 2, 2026. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-24-023.html.
Eligible Applicants
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.